Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases

Journal of Medicinal Chemistry

Volumn 55, Issue 6, 2012, Pages 2846-2857

  Cha, Mi Young ^a,b   Lee, Kwang Ok ^a   Kang, Seok Jong ^a   Jung, Young Hee ^a   Song, Ji Yeon ^a   Choi, Kyung Jin ^a   Byun, Joo Yun ^a   Lee, Han Jae ^b   Lee, Gwan Sun ^a   Park, Seung Bum ^b   Kim, Maeng Sup ^a  

^a Hanmi Pharmaceutical Co Ltd   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; N [[2 [4 AMINO 6 [3 CHLORO 4 (PYRIDIN 2 YLMETHOXY) PHENYLAMINO]PYRIMIDIN 5 YL]OXAZOL 4 YL]METHYL]ACRYLAMIDE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL TYPE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG APPROVAL; DRUG RESISTANCE; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MOUSE; MUTATION; NONHUMAN; RAT; SOLID TUMOR; STOMACH CANCER;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED ICR; MODELS, MOLECULAR; MUTATION; OXAZOLES; PYRIMIDINES; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84863389355     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201758g     Document Type: Article

References (28)

1. Schlessinger, J. Cell signaling by receptor tyrosine kinases Cell 2000, 103, 211-225
2. Hynes, N. E.; Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors Nat. Rev. Cancer 2005, 5, 341-354 (Pubitemid 40637826)
3. Yarden, Y.; Sliwkowski, M. X. Untangling the ErbB signaling network Nat. Rev. Mol. Cell Biol. 2001, 2, 127-137
4. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 1987, 235, 177-182 (Pubitemid 17231334)
5. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 1989, 244, 707-712 (Pubitemid 19147683)
6. Nahta, R.; Shabaya, S.; Ozbay, T.; Rowe, D. L. Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens Curr. Pharm. Pharmacogenomics Pers. Med. 2009, 7, 263-274
7. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 2002, 20, 719-726 (Pubitemid 34111379)
8. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 2001, 344, 783-792 (Pubitemid 32222155)
9. Wenle, X.; Mullin, R. J.; Keith, B. R.; Liu, L. H.; Ma, H.; Rusnak, D. W.; Owens, G.; Alligood, K. J.; Spector, N. L. Anti-tumor activity of GW-572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways Oncogene 2002, 21, 6255-6263
10. Johnston, S. R. D.; Leary, A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer Drugs Today 2006, 42, 441-453 (Pubitemid 44221014)
11. Speyer, J. Cardiac dysfunction in the trastuzumab clinical experience J. Clin.Oncol. 2002, 20, 1156-1157 (Pubitemid 34177417)
12. Abraham, J. Dual HER1/HER2 inhibitor lapatinib in advanced/metastatic breast cancer Commun. Oncol. 2007, 4, 73-78
13. Nahta, R.; Esteva, F. J. Herceptin: mechanisms of action and resistance Cancer Lett. 2006, 232, 123-138 (Pubitemid 43170962)
14. O'Brien, N. A.; Browne, B. C.; Chow, L.; Wang, Y.; Ginther, C.; Arboleda, J.; Duffy, M. J.; Crown, J.; O'Donovan, N.; Slamon, D. J. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib Mol. Cancer Ther. 2010, 9, 1489-1502
15. Köninki, K.; Barok, M.; Tanner, M.; Staff, S.; Pitkänen, J.; Hemmilä, P.; Ilvesaro, J.; Isola, J. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells Cancer Lett. 2010, 294, 211-219
16. Adjei, A. A. Epidermal growth factor receptor tyrosine kinase inhibitors in cancer therapy Drugs Future 2001, 26, 1087-1092 (Pubitemid 34059457)
17. Renhowe, P. A. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy-clinical progress Curr. Opin. Drug Discovery Dev. 2002, 5, 214-224 (Pubitemid 35012708)
18. Wissner, A.; Overbeek, E.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Mamuya, N.; Rosfjord, E. C.; Discafani, C.; Davis, R.; Shi, X.; Rabindran, S. K.; Gruber, B. C.; Ye, F.; Hallett, W. A.; Nilakantan, R.; Shen, R.; Wang, Y.; Greenberger, L. M.; Tsou, H. Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles: the design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2) J. Med. Chem. 2003, 46, 49-63 (Pubitemid 36043786)
19. Tsou, H. R.; Overbeek-Klumpers, E. G.; Hallett, W. A.; Reich, M. F.; Floyd, M. B.; Johnson, B. D.; Michalak, R. S.; Shen, R.; Shi, X.; Wang, Y. F.; Upeslacis, J.; Wissner, A. Optimization of 6,7-disubstituted-4-(arylamino) quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity J. Med. Chem. 2005, 48, 1107-1131 (Pubitemid 40270454)
20. Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K. K. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Oncogene 2008, 27, 4702-4711
21. Kamath, S.; Buolamwini, J. K. Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development Med. Res. Rev. 2006, 1-26
22. Shintani, S.; Matsuo, K.; Crohin, C. C. Intragenic mutation analysis of the human epidermal growth factor receptor (EGFR) gene in malignant human oral keratinocytes Cancer Res. 1999, 59, 4142-4147 (Pubitemid 29393590)
23. Wildenhain, Y.; Pawson, T.; Blackstein, M. E.; Andrulis, I. L. p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2 Oncogene 1990, 5, 879-883
24. Di, L.; Kerns, E. H.; Hong, Y.; Kleintop, T. A.; McConnell, O. J.; Huryn, D. M. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates J. Biomol. Screening 2003, 8, 453-462
25. Obach, R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes Drug Metab. Dispos. 1999, 27 (11) 1350-1359
26. Liu, L.; Greger, J.; Shi, H.; Liu, Y.; Greshock, J.; Annan, R.; Halsey, W.; Sathe, G. M.; Martin, A.; Gilmer, T. M. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL Cancer Res. 2009, 69, 6871-6878
27. Rusnak, D. W.; Alligood, K. J.; Mullin, R. J.; Spehar, G. M.; Arenas-Elliott, C.; Martin, A. M.; Degenhardt, Y.; Rudolph, S. K.; Haws, T. F., Jr.; Hudson-Curtis, B. L.; Gilmer, T. M. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines Cell Proliferation 2007, 40, 580-594 (Pubitemid 47063294)
28. Cha, M. Y.; Lee, K.-O.; Kim, J. W.; Lee, C. G.; Song, J. Y.; Kim, Y. H.; Lee, G. S.; Park, S. B.; Kim, M. S. Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer J. Med. Chem. 2009, 52, 6880-6888